CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
12 picks for an income portfolio - Q3 2025 update
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,299.00 | 21.90 | 0.24% |
CAC 40 | 7,919.62 | 14.64 | -0.18% |
DAX 40 | 24,236.94 | 150.99 | -0.62% |
Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
FTSE 100 | 9,452.77 | 9.90 | 0.10% |
HKSE | 25,923.23 | 481.88 | 1.89% |
NASDAQ | 22,521.70 | 172.91 | -0.76% |
Nikkei 225 | 47,685.84 | 838.52 | 1.79% |
NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
S&P 500 | 6,644.31 | 10.41 | -0.16% |
S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
SSE Composite Index | 3,904.76 | 39.53 | 1.02% |